1 / 30

Prof Flávio Danni Fuchs Professor Associado de Cardiologia, FAMED, UFRGS

Estado da arte em 2012. Prof Flávio Danni Fuchs Professor Associado de Cardiologia, FAMED, UFRGS Coordenador do INCT-IATS e Estudo PREVER Pesquisador IA do CNPq. Tratamento não-medicamentoso. Efetividade a longo prazo de abordagens não-medicamentosas (TOHP-II, Arch Intern Med 1997; 157:657).

aquila
Download Presentation

Prof Flávio Danni Fuchs Professor Associado de Cardiologia, FAMED, UFRGS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Estado da arte em 2012 Prof Flávio Danni Fuchs Professor Associado de Cardiologia, FAMED, UFRGS Coordenador do INCT-IATS e Estudo PREVER Pesquisador IA do CNPq

  2. Tratamento não-medicamentoso

  3. Efetividade a longo prazo de abordagens não-medicamentosas(TOHP-II, Arch Intern Med 1997; 157:657) Systolic BP (mmHg) Diastolic BP (mmHg) Months of follow-up

  4. Efeitos de dietas hipossódicas na excreção urinária de sódio (estudos de longa duração) 1 mmol de Na+ = 23 mg 40 mmol = 920 mg ∞ 1 g Taylor RS, et al. AJH 2011; 24: 843

  5. Efeitos de dietas hipossódicas na PAS Taylor RS, et al. AJH 2011; 24: 843

  6. Efeitos de dietas hipossódicas na PAD Taylor RS, et al. AJH 2011; 24: 843

  7. Efeitos de dietas hipossódicas na incidência de DCV Taylor RS, et al. AJH 2011; 24: 843

  8. Efeitos de dietas hipossódicas na incidência de eventos cardiovasculares (He FJ, MacGregor GA. Lancet 2011; 378: 380)

  9. Efetividade da adesão a MEV (23,8 meses)(Riegel G. AJH 2012; in press) Favorece Não-adesão Favorece adesão Delta Inter-grupos Recomendações Dieta hipossódica 5,1 (1,7-8,6) Sistólica 2,1 (0,2 - 3,9) Diastólica Dieta hipocalórica Sistólica 6,6 (2,9 - 10,2) 2,0 (0,1 - 3,9) Diastólica Exercícios 1,6 (-1,7 - 4,9) Sistólica 0,1 (-1,7 - 1,8) Diastólica -5,0 5,0 10,0 0 Delta de PA (mmHg)

  10. In the meantime, it is worthy to present the option to start low doses of BP agents for individuals who do not respond to the prescription of lifestyle modification.

  11. BP-lowering drugs: essentials for some patients with normal BP. (Fuchs FD. Expert Rev Cardiovasc Ther 2004; 2:89-94.) Condition Active Primary RRR (%) treatment outcome (95% CI) D. mellitus Ramipril MI, stroke or CV death 25 (12 to 36) Any evidence of Ramipril MI, stroke or CV death 22 (14 to 30) atherosclerosis Perindopril MI, CV death, c. arrest 20 (9 to 29) MI Beta-blocker Recurrent MI 22 (16 to 28) Stroke Indapamide Stroke 42 (19 to 58) plus perindopril Not overt HF Enalapril CV deaths 12 (-3 to 26) Overt HF Enalapril CV deaths 18 (6 to 28) Captopril 21 (5 to 35)

  12. Drug treatment among persons without hypertension Thompson AM, et al. JAMA 2011; 305:913-22.

  13. Drug treatment among persons without hypertension Thompson AM, et al. JAMA 2011; 305:913-22. Additional randomized trial data are necessary to assess these outcomes in patients without CVD clinical recommendations.

  14. Tratamento medicamentoso

  15. Diuretics are still essential drugs for hypertension management, but diuretics with higher potency and duration of action, such as chlorthalidone, should be preferred.

  16. Clortalidonabombando

  17. Novas análises do MRFIT - PA Dorsch MP. Hypertension 2011; 57:689-694

  18. Novas análises do MRFIT - Eventos Dorsch MP. Hypertension 2011; 57:689-694

  19. Novidades sobre losartana e parentes

  20. European revised (2009) Journal of Hypertension. doi:10.1097/HJH.0b013e3281fc975a

  21. ARB and the prevention of atrial fibrillation - I The GISSI-AF Investigators. N Engl J Med 2009; 360:1606-17.

  22. ARB and the prevention of atrial fibrillation-II ACTIVE. NEJM 2011; 364:928-38.

  23. INCIDENCE OF MICROALBUMINURIA IN TYPE 1 DIABETESMauer M, et al. N Engl J Med 2009;361:40-51. 6 4 17 %

  24. ONTARGET – RISCOS DO DUPLO BLOQUEIONEJM 2008; 338:b1665. Risco ramipril Risco associação Revascularização 1.04 (0.97–1.13) Insuficiência cardíaca 0.94 (0.83–1.07 Fibrilação atrial 0.96 (0.85–1.07) Piora função renal 1.33 (1.22–1.44) Ins renal terminal 1.37 (0.94–1.98) 0,5 2,0 1,0

  25. Efeitos renais em trials recentes ROADMAP (N Engl J Med 2011; 364:907): the reduction in glomerular filtration rate was higher in patients treated with olmesartan instead of placebo (P<0.001). ACTIVE (N Engl J Med 2011; 364:928): the incidence of renal dysfunction leading to discontinuation of the drug almost doubled in patients treated with irbesartan (0.95%) than placebo (0.53%), P = 0.02. TRANSCEND (Ann Intern Med 2009; 151:1-10): the decreasing in glomerular filtration rate was greater with telmisartan than with placebo (P < 0.001)

  26. E háoutraspreocupações

  27. Risk for control Risk for ARB Control STUDY RR Outcome 0.76 (0.58–0.98) Atenolol Composite CV LIFE (losartan) 1.19 (1.02-1.38) Amlodipine MI VALUE (valsartan) 1.01 (0.94–1.09) Composite CV Ramipril ONTARGET (telmisartan) 0.89 (0.76-1.06) Composite CV Placebo SCOPE (candesartan) 0.92 (0.82-1.05) Composite CV Placebo TRANSCEND (telmisartan) 0.95 (0.86-1.04) Stroke Placebo PROFESS (telmisartan) 0.99 (0.86-1.14) Composite CV Placebo NAVIGATOR (valsartan) 0.99 (0.91-1.08) Composite CV Placebo ACTIVE (irbesartan) 4.94 (1.43–17.06) Placebo Mortality CV ROADMAP (olmesartan) 3.36 (0.93-12.07) ORIENT (olmesartan) Placebo Mortality CV 0.5 1.0 1.5 5.0

  28. ARB do not cause myocardial infarction Messerli FH et al. BMJ 2011; 342:d2234.

  29. ARB do not cause myocardial infarction Messerli FH. BMJ 2011; 342:d2234.

  30. When

More Related